

## I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	5 390 000	53
Low transmission (0-1 cases per 1000 population)	4 780 000	47
Malaria-free (0 cases)	0	0
Total	10 170 000	


Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. albimanus</i>
Programme phase: Control	

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2012
	ITNs/LLINs distributed to all age groups	Yes	2012
<b>IRS</b>	IRS is recommended	No	-
	DDT is used for IRS	No	-
<b>Larval control</b>	Use of larval control	Yes	2011
<b>IPT</b>	IPT used to prevent malaria during pregnancy	N/A	-
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	1988
	Malaria diagnosis is free of charge in the public sector	Yes	2011
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	-
	Artemisinin-based monotherapies withdrawn	-	-
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	-
	System for monitoring of adverse reaction to antimalarials exists	No	-

Intervention	Policies/strategies	Yes/No	Year adopted
<b>Surveillance</b>	ACD for case investigation (reactive)	Yes	-
	ACD at community level of febrile cases (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-
<b>Antimalaria treatment policy</b>			<b>Year adopted</b>
First-line treatment of unconfirmed malaria		-	-
First-line treatment of <i>P. falciparum</i>		CQ+PQ(1d)	-
For treatment failure of <i>P. falciparum</i>		-	-
Treatment of severe malaria		-	-
Treatment of <i>P. vivax</i>		CQ+PQ(14d)	-
Dosage of primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/kg (14 days)	-
Type of RDT used		<i>P. f. only</i>	
<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>			
<b>Medicine</b>	<b>Year</b>	<b>Min</b>	<b>Median</b>
		<b>Max</b>	<b>Follow-up</b>
		<b>No. of studies</b>	<b>Species</b>


## III. Financing




## Expenditure by intervention in 2012




## IV. Coverage






## Cases tested and potentially treated (public sector)



## V. Impact



## Proportion of malaria cases due to *P. vivax*



**Impact:** Insufficiently consistent data to assess trends